Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Protein Sciences announced the approval of an extended shelf life for Flublok Quadrivalent vaccine from 6 to 9 months.
Flublok Quadrivalent, a recombinant high-antigen vaccine, confers protection against four strains of the influenza virus and has three times the active ingredients than other quadrivalent flu vaccines. In a large clinical study, greater efficacy was seen with Flublok Quadrivalent vs. a standard quadrivalent flu vaccine in adults ≥50 years. Patients who were administered Flublok Quadrivalent had a 43% reduced risk of getting culture-confirmed influenza vs. patients who received the standard vaccine.
Flublok Quadrivalent was approved by the FDA in October 2016 for use in adults aged >18 years; Trivalent Flublok was launched in 2013. Flublok is developed in a 100% egg-free system and is highly purified. It does not contain any preservatives, egg proteins, gelatin or latex.
Flublok Quadrivalent will be available in prefilled syringes for the upcoming flu season. Shipments are expected to commence in August.
For more information call (800) 488-7099 or visit Flublok.com.
